Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, is pleased to announce the publication of its 2017 Annual Report and the invitation to its Ordinary General Shareholders’ meeting.
The Annual Report which outlines Mithra’s achievements in 2017 includes the following information:
François Fornieri, CEO Mithra : “2017 has been a crucial year of progress for Mithra during which we advanced our key clinical programs. These include the pivotal Phase III trials of our innovative 5th generation oral contraceptive, Estelle®, and the Phase II study of Donesta®, our novel candidate for menopausal symptoms. Also, business development activity accelerated significantly, marked by important commercialization contracts, including Libbs for Estelle® in Brazil, Fuji Pharma for Donesta® in Japan and Mayne Pharma for Myring™ in the US.
We look forward to building on the progress made to date, with important read-outs for both the Donesta® and Estelle® clinical trials during 2018, and the addition of commercial partners for our portfolio in new territories. We are confident that with Donesta® and Estelle®, we have two potential blockbusters in our pipeline that position Mithra for long-term international growth as a transformational leader in Women’s Health.”
Mithra releases its Annual Report in English and French. In case of interpretation differences, the French version will prevail. The report is available in English and French and can be downloaded on the website investors.mithra.com as a PDF file.
The Ordinary General Shareholders’ meeting of Mithra Pharmaceuticals will be held on May 17 2018 at 5:00 PM (CEST) in Liège (Belgium). Mithra is pleased to invite its shareholders.
The notice for the Ordinary General Shareholders’ meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in women's health, with a particular focus on fertility, contraception and menopause. Mithra's goal is to develop new and improved products that meet women's needs for better safety and convenience. Its two lead development candidates - a fifth generation oral contraceptive, Estelle®, and a next generation hormone therapy, Donesta® - are built on Mithra's unique native estrogen platform (E4). Mithra also develops and markets complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its Mithra CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by Mr. François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com